Skip to main content

Diabetic Macular Oedema

2
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
Intravitreal injection of pegaptanib sodiumPhase 41 trial
Active Trials
NCT01175070Completed30Est. Mar 2013
Innovent Biologics
Innovent BiologicsChina - Jiangsu
1 program
1
IBI302Phase 21 trial
Active Trials
NCT06908876Recruiting150Est. Feb 2027
Optos
OptosUK - Dunfermline
1 program
PASCAL Laser, Green Laser 0.75N/A1 trial
Active Trials
NCT02309476Withdrawn0Est. Dec 2015
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
dexamethasone intravitreal implantN/A1 trial
Active Trials
NCT02731911Completed202Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
PfizerIntravitreal injection of pegaptanib sodium
Innovent BiologicsIBI302
AbbViedexamethasone intravitreal implant
OptosPASCAL Laser, Green Laser 0.75

Clinical Trials (4)

Total enrollment: 382 patients across 4 trials

NCT01175070PfizerIntravitreal injection of pegaptanib sodium

Intravitreal Macugen for Ischaemic Diabetic Macular Oedema

Start: Jan 2011Est. completion: Mar 201330 patients
Phase 4Completed
NCT06908876Innovent BiologicsIBI302

A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）

Start: Apr 2025Est. completion: Feb 2027150 patients
Phase 2Recruiting
NCT02731911AbbViedexamethasone intravitreal implant

Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study

Start: Apr 2016Est. completion: Oct 2018202 patients
N/ACompleted
NCT02309476OptosPASCAL Laser, Green Laser 0.75

Sub-threshold Photocoagulation of Diabetic Macular Oedema

Start: Oct 2012Est. completion: Dec 20150
N/AWithdrawn

Related Jobs

Associate Director, U.S. Marketing Ophthalmology HCP Field Execution

Verona PharmaVerona Pharma
USA - Pennsylvania - North Wales (Upper Gwynedd) (Hybrid)
6d ago
$142K - $224K/yr

Associate Director, U.S. Marketing Ophthalmology HCP Field Execution

Merck & Co.Merck & Co.
USA - Pennsylvania - North Wales (Upper Gwynedd) (Hybrid)
6d ago
$142K - $224K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 382 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.